The Conference was attended by over 450 delegates – representatives of state authorities, scientific and expert community, Russian and international pharmaceutical companies and associations as well as leading health technology assessment (HTA) and drug supply professionals from different countries.
The event was supported by the Ministry of Health of the Russian Federation (RF), the Ministry of Finance of the RF, Council of the Federation Committee for Social Policy of the Federal Assembly of the Russian Federation, Federal State Budgetary Institution (FSBI) «Center for Healthcare Quality Assessment and Control» of the RF Ministry of Health, FSBI «Financial Research Institute» of the RF Ministry of Finance, the Skolkovo Foundation and the National Center for Health Technology Assessment.
The Conference was focused on the experience of integrating HTA into the decision-making system in the Russian Federation and the European Union and introducing clinical guidelines into healthcare practice in the CIS countries.
The Conference was opened by Galina Karelova, the Vice-Chairman of The Council of Federation of the Federal Assembly of the Russian Federation. She emphasized the timeliness and importance of the subject and reminded the participants that first legislative steps towards implementation of health technology assessment in Russia had been initiated by members of the Federation Council and the Federation Council Committee for Social Policy. In his welcome speech addressed to the delegates Valery Ryazansky, the Chair of the Federation Council Committee for Social Policy, accentuated the importance of innovative technologies for healthcare too, but at the same time he mentioned the need for optimization of state expenditures for healthcare which should be of systematic and scientific nature.
In his speech Vladimir Nazarov, the Director of the Financial Research Institute of the RF Ministry of Finance, talked about the existing healthcare financing problems and underlined that cost effectiveness in our country in terms of the achieved life expectancy rate is much lower than the same rate in Eastern European countries.
Vitaly Omelyanovsky, the General Director of the Center for Healthcare Quality Assessment and Control of the RF Ministry of Health, talked about healthcare effectiveness assessment and quality control system and discussed the prospects for HTA development in the context of complicated economic environment.
Elena Maksimkina, the Director of the Department for Drug Provision and Regulation of Medical Devices Circulation of the RF Ministry of Health, devoted her speech to the tendencies in introducing hi-tech medical care in our country and the problems associated with assessment of their effectiveness. She noted that for the purposes of better objectivity and transparency it is necessary to establish a system with perfectly defined assessment criteria, comparison parameters or scales and the ranking of such criteria according to their importance.
The issue of innovative technology assessment from the perspective of an investment foundation was addressed by Kirill Kayem, the Vice President of the Skolkovo Foundation and the Executive Director for biomedical technology cluster.
Several international experts shared their presentations: Iñaki Gutiérrez-Ibarluzea representing the Basque Office for HTA discussed the international experience of excluding ineffective technologies and medicines from state financing programs; Chris Henshall from the Brunel University (UK) and Simona Montilla from the Italian Medicines Agency talked about various HTA systems and approaches in European countries.
Western countries’ experience proves that in the context of economic crisis the requirements to HTA become “tougher” for innovative technologies to enter the state financing system. In Russia innovative products are introduced alongside with other products, the factor of innovativeness is neither assessed nor registered; new technologies are neither searched nor monitored.
Comprehensive assessment of new health technologies should contribute greatly to decision-making effectiveness improvement, providing helpful and up-to-date information on new health technologies from the viewpoint of their introduction (or refusal to introduce) into the healthcare system.
The investigated technologies that have proved to be effective, safe and economically acceptable should be recommended to be included in clinical guidelines and – first of all – used for hi-tech medical care for patients. For pharmaceuticals, this stage should be associated with their inclusion into the Vital and Essential Drug List and other lists.
The Conference concluded with adoption of a resolution in which its participants set forth their recommendations to State Duma deputies and Federation Council members to support amendments to Federal Law No. 323 “On Fundamental Healthcare Principles in the Russian Federation” and Federal Law No. 180 “On Biomedical Cellular Products” in terms of health technology assessment system introduction as well as recommendations to the RF Government and the RF Ministry of Health to accelerate adoption of required legal acts and regulations for the purpose of implementing Federal Law No. 429-FZ dated 22.12.2014, including the legal act on comprehensive assessment of medicines purchased from budget and compulsory medical insurance funds.